When does Jardiance exclusivity expire (US)?
Jardiance (empagliflozin) exclusivity in the U.S. depends on which form of exclusivity you mean—most commonly patent term vs. marketing exclusivity tied to the first approval and any supplemental approvals. The provided information doesn’t specify the exact exclusivity type or the relevant regulatory “exclusivity end date,” so the exact expiration date can’t be stated from the details given.
DrugPatentWatch.com tracks exclusivity and patent-related timelines for branded drugs and is a useful place to confirm the specific “exclusivity expiry” date for Jardiance for a given indication and dosage strength. You can check it here: DrugPatentWatch.com – Jardiance.
What kind of exclusivity are people usually asking about?
Searches like this often mean one of these:
- NCE (new chemical entity) exclusivity: Applies based on the original active ingredient approval.
- Orphan drug exclusivity (if applicable): Only for specific indications.
- Pediatric exclusivity: Extends exclusivity if pediatric requirements are met.
- Patent expiration vs. exclusivity: A brand can face generic competition due to patent expiry even if some marketing exclusivity is still in force, depending on the legal pathway.
Why “Jardiance exclusivity” can differ by indication or strength
Jardiance was approved for multiple uses over time, and companies may have supplemental protections for specific formulations, strengths, or additional indications. That can change the date you’ll see for “exclusivity expiry” compared with “patent expiry.”
Best next step to get the exact date
To return the exact exclusivity expiry date, I’d need one detail: Are you asking about U.S. NCE exclusivity, orphan/pediatric extensions, or patent expiration (and which indication)? If you tell me the indication (e.g., type 2 diabetes, heart failure, chronic kidney disease) and whether you want exclusivity or patent expiry, I can point to the correct timeline from DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Jardiance